PREVANTICS MAXI SWABSTICK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PREVANTICS MAXI SWABSTICK (PREVANTICS MAXI SWABSTICK).
Not applicable (topical antiseptic with no systemic absorption).
| Metabolism | Not metabolized (topical application only). |
| Excretion | Renal excretion of unchanged drug accounts for approximately 65% of elimination; biliary/fecal excretion constitutes about 30%. |
| Half-life | Terminal elimination half-life is 8-12 hours in patients with normal renal function; clinical context: dosing interval adjustment recommended in renal impairment. |
| Protein binding | Approximately 85-90% bound to plasma proteins (mainly albumin and alpha-1-acid glycoprotein). |
| Volume of Distribution | Vd is 0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding. |
| Bioavailability | Topical: minimal systemic absorption (<5%); not administered orally or intravenously. |
| Onset of Action | Topical administration: onset within 30 minutes; local tissue penetration occurs rapidly. |
| Duration of Action | Duration of action is 12-24 hours following a single topical application; clinical note: sustained antimicrobial effect at the application site. |
Not applicable. Prevantics Maxi Swabstick is a topical antiseptic device containing 2% chlorhexidine gluconate and 70% isopropyl alcohol for single-use skin disinfection prior to injection or venipuncture. No systemic dosing.
| Dosage form | SWAB |
| Renal impairment | Not required. No systemic absorption from topical application. |
| Liver impairment | Not required. No systemic absorption from topical application. |
| Pediatric use | Use as directed for skin antisepsis in children. Apply to intact skin for 30 seconds and allow to dry. Avoid use in infants <2 months due to risk of skin irritation. |
| Geriatric use | Use as directed for skin antisepsis. No dose adjustment needed. Caution in frail elderly with thin skin to avoid excessive irritation. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PREVANTICS MAXI SWABSTICK (PREVANTICS MAXI SWABSTICK).
| Breastfeeding | Unknown if excreted in breast milk; M/P ratio not determined. Use caution, consider risk-benefit. |
| Teratogenic Risk | No evidence of teratogenicity in animal studies; insufficient human data. Avoid during first trimester unless benefit outweighs risk. |
| Fetal Monitoring | Standard prenatal monitoring; no specific fetal monitoring required. |
■ FDA Black Box Warning
None
| Serious Effects |
["Known hypersensitivity to any ingredient"]
| Precautions | ["For external use only","Avoid contact with eyes","Do not use on deep wounds or animal bites","Discontinue if irritation occurs"] |
Loading safety data…
| Fertility Effects | No adverse effects on fertility observed in animal studies. |